Neoplastic Diseases

  • Kenneth F. Kessel
  • William T. Leslie
  • Arthur H. Rossof

Abstract

The single most important diagnostic principle concerning malignant neoplasm is its earliest possible detection. Success depends on patient and physician awareness of the cancer Screening tests available and their recommended frequency. The American Cancer Society and other organizations have utilized mass media to inform the public of its responsibility for routine examination and reporting early signs and symptoms to a physician. Unfortunately, some of the most common cancers do not lend themselves to Screening of asymptomatic people (lung, prostate, and ovary), whereas others require patient self-examination for early detection (breast, testes). The current recommendations for cancer Screening are summarized in Table 34.1.1–3 In addition, patient education, including self-examination and knowledge of early signs and symptoms of cancer, is an essential role of the family physician.

Keywords

Fatigue Lymphoma Morphine Breast Pancreas Testosterone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Frame PS. A critical review of adult health maintenance. 3. Prevention of cancer. J Fam Pract 1986; 22: 511–20.PubMedGoogle Scholar
  2. 2.
    American Cancer Society. ACS report on the cancer-related health check-up. CA 1980; 30: 194–240.Google Scholar
  3. 3.
    Canadian Task Force on the Periodic Health Examination. The periodic health examination. 2. 1984 update. Can Med Assoc J 1984; 130: 1278–85.Google Scholar
  4. 4.
    CA Age-Adjusted Cancer Death Rates for Selected Sites Females, Males, United States, 1930–1982. U.S. National Center for Health Statistics and U.S. Bureau of the Census. 1986; 36: 14–5.Google Scholar
  5. 5.
    Bailar JC III, Smith EM. Progress against cancer. N Engl J Med 1986; 314: 1226–32.PubMedCrossRefGoogle Scholar
  6. 6.
    Lynch HT. Hereditary cancer: ascertainment and management. CA 1979; 29: 216–229PubMedGoogle Scholar
  7. 7.
    Fed Register Rules and Regulations. 1983; 48:No. 243.Google Scholar
  8. 8.
    De Vita V, Hellman S, Rosenberg S. Cancer: principles & practice of oncology. 2nd ed. Philadelphia: Lippincott, 1985.Google Scholar
  9. 9.
    Hände K, DesPrez R. Current perspective in small cell lung cancer. Chest 1984; 85: 669–75.PubMedCrossRefGoogle Scholar
  10. 10.
    Bone RC, Balk R. Staging of bronchogenic carcinoma. Chest 1982; 82: 473–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Klatersky J, Sculier JP. Chemotherapy of non-small cell lung cancer. Semin Oncol 1985;(suppl 6)4:38–44.Google Scholar
  12. 12.
    Henderson IC, Canellos GP. Cancer of the breast: the past dec-ade. N Engl J Med 1980;302: 17–30, 78–90.Google Scholar
  13. 13.
    Fisher B, Bauer M, Margolese R. Five-year results of a randomized clinical trial comparing total mastectomy and segmented mas-tectomy with or without radiation in the treatment of breast cancer. N Engl J Med 1985; 312: 665–714.PubMedCrossRefGoogle Scholar
  14. 14.
    Levine R, Lippman M. Breast cancer management: recent ad-vances and recommendations. Adv Intern Med 1984; 29: 215–20.PubMedGoogle Scholar
  15. 15.
    Taylor S, Kalish L. Adjuvant CMFP versus CMFP plus tamoxifen etc. J Clin Oncol 1985; 3: 192–6.Google Scholar
  16. 16.
    Stein S. C02 laser surgery of the cervix, vagina & vulva. Surg Clin North Am 1984; 64 (5): 56–64.Google Scholar
  17. 17.
    Tannock IF. Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? J Clin Oncol 1985; 3: 1013–20.PubMedGoogle Scholar
  18. 18.
    O’Connell M. Current status of chemotherapy for advanced pancreatic and gastric cancer. Clin Oncol 1985; 3: 1032–6.Google Scholar
  19. 19.
    Malt R. Treatment of pancreatic cancer. JAMA 1983; 250: 1433–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Simon J. Occult blood Screening for colorectal carcinoma: a critical review. Gastroenterology 1985; 88: 820–5.PubMedGoogle Scholar
  21. 21.
    Canellos G, Come S, Skarin A. Chemotherapy in the treatment of Hodgkin’s disease. Semin Hematol 1983; 20: 1–12.PubMedGoogle Scholar
  22. 22.
    Hoppe RT. Stage I—II Hodgkin’s disease: current therapeutic op-tions and recommendations. Blood 1983; 62: 32–7.PubMedGoogle Scholar
  23. 23.
    Bonadonna G, Valagussa P, Santoro A. Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin’s disease. Ann Intern Med 1986; 104: 739–46.PubMedCrossRefGoogle Scholar
  24. 24.
    Williams W, Beutler E, Erslev AJ, Lichtman MA, eds. Hematol-ogy. New York: McGraw-Hill, 1983.Google Scholar
  25. 25.
    Brain, M, Carbone P. Current therapy in hematology-oncology 1985–1986. St. Louis: Mosby, 1985.Google Scholar
  26. 26.
    Cassileth P, ed. Symposium on hematology and hematologic ma-lignancies. Med Clin North Am 1984; 68: 531–792.Google Scholar
  27. 27.
    Lister T, Rohatiner AS. The treatment of acute myelogenous leu-kemia in adults. Semin Hematol 1982; 19: 172–7.PubMedGoogle Scholar
  28. 28.
    Bergsagel D. Controversies in the treatment of plasma cell myeloma. Postgrad Med J 1985; 61: 109–16.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Kenneth F. Kessel
  • William T. Leslie
  • Arthur H. Rossof

There are no affiliations available

Personalised recommendations